Spyre Therapeutics

US · SYRE #1646 by market cap Listed 1970

80.85 +0.74 +0.92%

Live - 5344 symbols - heartbeat 424s ago · 2026-10-08 07:00

Pre-market 80.50 -0.43%

After-hours 81.22 +0.46%

Overnight 79.62 -1.52%

Market cap: 7.13B
P/E (TTM): -40.83
P/B: 7.47
EPS: -1.98
Div yield: 0.00%
52W pos: 68%

Reader sentiment Are you bullish or bearish on SYRE?

Anonymous reader poll. Unscientific, not investment advice.

About Spyre Therapeutics

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Founded: 2013
CEO: Dr. Cameron Turtle, D.Phil.
Employees: 102
Headquarters: Waltham, Massachusetts, United States of America
Fiscal year end: 12-31
Website: spyre.com

Company profile

Exchange: US
Symbol: SYRE
Market-cap rank: #1646
Listing date: 1970-01-01
Market cap: 7.13B
Float cap: 6.27B
Shares out: 88.17M
Float shares: 77.61M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 07:00:13 · For reference only, not investment advice and not tailored to your situation.